Aaron Gerds
Cleveland Clinic Taussig Cancer Institute · Cleveland Clinic, Case Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Aaron Gerds as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05835466 · Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)Icahn School of Medicine at Mount Sinai · recruiting · Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF) · study chair
- Ph1/Ph2NCT04629651 · Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative NeoplasmsCase Comprehensive Cancer Center · withdrawn · Bone Marrow Fibrosis, Myeloproliferative Neoplasm · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Case Comprehensive Cancer Center NCTN Lead Academic Participating SiteUG1CA233234 · NCI · CASE WESTERN RESERVE UNIVERSITY · fiscal years 2019 to 2026 · $1,218,418 awarded in 2026Same name and institution; not confirmed by an ID
- Clinical Protocol and Data ManagementP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · fiscal years 2020 to 2024 · $753,139 awarded in 2024Same name and institution; not confirmed by an ID
- CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating SiteU10CA180853 · NCI · CASE WESTERN RESERVE UNIVERSITY · fiscal years 2018 · $1,187,291 awarded in 2018Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:33 UTC. The ranking covers the 200 most relevant of 33 PubMed records, and a shared surname and initials can bring in a namesake. All 33 on PubMed
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.JAMA Oncol · 2018355 citationsRCR 11.4
- 184 citationsRCR 17.9
- ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.Blood Adv · 2020117 citationsRCR 5.4
- Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.Blood Adv · 202088 citationsRCR 4.2
- Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.Blood Adv · 202066 citationsRCR 2.9
- Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.Nat Med · 202563 citationsRCR 15.9
- Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.Leukemia · 202262 citationsRCR 4.8
- Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.N Engl J Med · 202451 citationsRCR 8.4
- Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.Leuk Res · 201847 citationsRCR 1.7
- Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.Blood · 202146 citationsRCR 2.6